Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Celgene Diversifies With $7.2B Receptos Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

Celgene sees Receptos' ozanimod as a potential best-in-class drug for MS and inflammatory diseases like ulcerative colitis, largely because the S1P receptor modulator appears to have a lower CV and liver risk than other therapies in the class.

Advertisement

Related Content

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register